3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Carcinoma, Non-Small-Cell Lung
448
Melanoma
287
Squamous Cell Carcinoma of Head and Neck
229
Parkinson Disease 4, Autosomal Dominant Lewy Body
188
Neoplasms
180
Breast Neoplasms
161
Triple Negative Breast Neoplasms
160
Neoplasm Metastasis
155
Lung Neoplasms
140
Colorectal Neoplasms
140
Carcinoma, Renal Cell
129
Head and Neck Neoplasms
120
Stomach Neoplasms
103
Ovarian Neoplasms
100
Carcinoma, Transitional Cell
91
Urinary Bladder Neoplasms
80
Pancreatic Neoplasms
80
Endometrial Neoplasms
72
Carcinoma, Hepatocellular
72
Uterine Cervical Neoplasms
63
Esophageal Neoplasms
57
Recurrence
52
Prostatic Neoplasms
48
Sarcoma
43
Carcinoma
42
Glioblastoma
39
Carcinoma, Squamous Cell
39
Small Cell Lung Carcinoma
38
Hodgkin Disease
36
Lymphoma
34
Interventions
Gemcitabine
30
Mitomycin
25
BCG Vaccine
11
Docetaxel
10
Epirubicin
6
erdafitinib
5
durvalumab
5
Radiotherapy
5
dodecyl maltoside
4
apaziquone
4
tislelizumab
3
Cystoscopy
3
ALT-803
3
viscum album peptide
2
pembrolizumab
2
disitamab vedotin
2
avelumab
2
VB4-845
2
Therapeutics
2
Imiquimod
2
Hyaluronic Acid
2
5-aminolevulinic acid hexyl ester
2
1-phenyl-3,3-dimethyltriazene
2
vocimagene amiretrorepvec
1
valrubicin
1
tremelimumab
1
toripalimab
1
pirarubicin
1
pemigatinib
1
monalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Non-Muscle Invasive Bladder Neoplasms
×
pembrolizumab
×
Clear all
NCT04387461
2024-09-25
CORE-001
CG Oncology, Inc.
Phase 2
Completed
35 enrolled
NCT03167151
2020-07-31
PemBla
University of Oxford
Phase 1/2
Terminated
6 enrolled
12 charts